tbuckley/cabot-search huggingface dataset:
C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease
Authors: Morten Dahl, Jørgen Vestbo, Peter Lange, Stig E. Bojesen, Anne Tybjærg-Hansen, Børge G. Nordestgaard
Journal: American Journal of Respiratory and Critical Care Medicine (2006)

Rationale: Patients with chronic obstructive pulmonary disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring serum C-reactive protein (CRP).Objective: To determine whether increased serum CRP in individuals with airway obstruction predicts future hospitalization and death from COPD.Methods: We performed a cohort study with a median of 8-yr follow-up of 1,302 individuals with airway obstruction selected from the ongoing Copenhagen City Heart Study.Measurements and Main Results: We measured serum CRP at baseline, and recorded COPD admissions and deaths as outcomes. During follow-up, 185 (14%) individuals were hospitalized due to COPD and 83 (6%) died of COPD. Incidences of COPD hospitalization and COPD death were increased in individuals with baseline CRP > 3 mg/L versus ⩽ 3 mg/L (log rank: p < 0.001). After adjusting for sex, age, FEV1% predicted, tobacco consumption, and ischemic heart disease, the hazard ratios for hospitalization and death due to COPD were increased at 1.4 (95% confidence interval, 1.0–2.0) and 2.2 (1.2–3.9) in individuals with baseline CRP > 3 mg/L versus ⩽ 3 mg/L. After close matching for FEV1% predicted and adjusting for potential confounders, baseline CRP was, on average, increased by 1.2 mg/L (analysis of variance: p = 0.002) and 4.1 mg/L (p = 0.001) in those who were subsequently hospitalized or died of COPD, respectively. The absolute 10-yr risks for COPD hospitalization and death in individuals with CRP above 3 mg/L were 54 and 57%, respectively, among those older than 70 yr with a tobacco consumption above 15 g/d and an FEV1% predicted of less than 50.Conclusions: CRP is a strong and independent predictor of future COPD outcomes in individuals with airway obstruction.
Universal Health Care Coverage
Authors: Harold S. Luft
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction—a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II)
Authors: Gunnar Frostfeldt, Greger Ahlberg, Gunnar Gustafsson, Gunnar Helmius, Bertil Lindahl, Anders Nygren, Agneta Siegbahn, Eva Swahn, Per Venge, Lars Wallentin
Journal: Journal of the American College of Cardiology (1999)
Abstract 2603: Predictors of Coronary Artery Visualization in Kawasaki Disease in the Pediatric Heart Network (PHN) Multi-Center Study
Authors: Renee Margossian, Minmin Lu, L. L Minich, Timothy Bradley, Meryl S Cohen, Jennifer S Li, Beth F Printz, Girish Shirali, Jane W Newburger, Steven D Colan
Journal: Circulation (2008)

Background: Echocardiography is the imaging modality of choice for evaluation of coronary artery (CA) abnormalities in Kawasaki disease (KD). Single center series have established high specificity and sensitivity for abnormality detection. Objective: To determine visualization rates of CAs across clinical centers and factors associated with success. Methods: Subjects enrolled in an 8 center PHN prospective, randomized trial of pulse steroids in primary treatment of KD underwent standardized echo evaluation at diagnosis and at 1 and 5 weeks later. All studies were interpreted by local centers and at a core laboratory (lab) which provided training and feedback over the study period. Imaging rates were calculated for each tertile of study time (9 month blocks). We explored univariate and multivariate predictors of CA visualization. Results: The core lab evaluated 587 echoes from 199 patients over 27 months. Left main, proximal/distal left anterior descending (LAD) and proximal right CAs were verified as visualized by the core lab in 91–98% of studies, but less often for the distal right (65%), circumflex (86%) and posterior descending (PD) (54%) CA segments. Visualization rates for 2 of the 3 less successfully imaged segments improved with time (p&lt;.05). Weight and BSA did not impact success. In multivariate analysis, local center, CA segment and time from study start to echo were independent predictors of visualization (all p&lt;.001). For CA segments for which % visualization varied by center, higher % visualization was associated with larger center volume (p=.001). Use of routine sedation was also associated with higher % visualization: distal LAD odds ratio (OR) 2.32 (95% CI 1.2, 4.49; p = 0.13), distal right OR 9.09 (95% CI 5.38, 15.35; p&lt;.001), circumflex OR 2.94 (95% CI 1.61, 5.38; p&lt;.001), PD OR 2.77 (95% CI 1.7, 4.53; p&lt;.001). Moderate agreement between local and core lab readings (ICC 0.55– 0.70) was present for all CA segments except the PD (ICC 0.38). Conclusion: Successful visualization of CAs in KD is associated with the specific CA segment being evaluated, and is influenced by center volume and sedation use. Increased visualization rates over time suggest a learning curve and underscore the value of core lab oversight in pediatric multi-center trials.
BRACHIAL PLEXUS NERVE BLOCK
Authors: EDWARD M. HANRAHAN
Journal: JAMA (1928)

Brachial plexus nerve block for operations on the arm is a form of regional anesthesia that has apparently found little favor in this country. This fact is somewhat surprising, as the procedure offers quite as striking advantages in its field as does the analogous sacral nerve block so popular in genito-urinary surgery. The most recent report, and in fact the only report other than those in specialized textbooks of the clinical application of brachial plexus block is that of Livingston and Wertheim.<sup>1</sup>They summarized the results in 1,000 cases reported in foreign journals, and added 105 of their own cases. Farr<sup>2</sup>has used the method many times. He states that it gives excellent anesthesia; its accomplishment is not difficult, and provided the injection is made slowly and with certain precautions, it is comparatively safe. The very satisfactory results that I have had with the procedure over a period
An uncomfortable ride
Authors: Fiona Godlee
Journal: BMJ (2005)

Whatever the pros and cons for patients, the UK's healthcare reforms promise an uncomfortable ride for doctors. The BMJ 's series on the NHS revolution, which continues this week, may be a wake-up call for doctors who haven't yet seen the writing on the wall.

Competition is changing the face of health care in the UK. As Nick Timmins explains (p 1193), competition in secondary care has already forced both the NHS and the private sector to change their behaviour. In response to the first wave of independent sector treatment centres (ISTCs), provided mainly by foreign contractors, BUPA …
Abstract 1375: A homogeneous high-throughput screening assay for inhibitors of the interaction of MLL-AF4 and AF9 in pediatric leukemia
Authors: Katherine Drake, Andrew D. Napper
Journal: Cancer Research (2011)

Abstract Chromosomal translocations of the mixed lineage leukemia (MLL) gene occur in 5-10% of pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), including up to 80% of infant ALL and most treatment-related secondary AML. These MLL rearrangements result in a portion of the MLL protein being fused to one of a number of transcription factors. The prognosis for MLL-rearranged (MLL-R) leukemia is much poorer than for leukemia devoid of MLL fusions; five-year survival of &amp;lt;40% in the case of infant ALL. MLL fusions are potent inducers of leukemia, through recruitment of a protein complex that activates transcription of the HOX (homeobox) oncogene HOXA9, which in turn blocks normal differentiation of progenitor cells and confers a stem cell-like phenotype. The transcription factor AF4 is the most common MLL fusion partner, and MLL-AF4 is associated with a particularly poor prognosis. Direct interaction of MLL-AF4 with the transcription factor AF9 has been shown to be critical to leukemic transformation. Here we describe the development of a homogeneous high-throughput screening (HTS) assay for small-molecule inhibitors of the binding of MLL-AF4 to AF9 and the validation of this assay in pilot HTS. A recent study showed that peptides containing as few as 10 amino acids derived from the AF9 binding site in AF4 bind to AF9 with low nanomolar potency and selectively kill MLL-AF4-containing leukemia cell lines. We have developed an assay that measures binding of an AF4-derived peptide to AF9 protein using AlphaScreen technology, a homogeneous proximity-based method well suited to HTS in 384- and 1536-well plates. Laser excitation of donor beads results in the generation of singlet oxygen, which encounters acceptor beads brought into close proximity by the binding of AF4 peptide to AF9, giving an amplified luminescent signal. Inhibitors are identified by reduction of the luminescent signal. We have validated the assay by demonstrating low nanomolar inhibition by several AF4-derived peptides and by screening a library of 2000 drugs and natural products. The next step is transfer of the assay to the Broad Institute (Cambridge, MA) for HTS against the 400,000-compound NIH library. The ultimate goal is the optimization of lead compounds as novel therapies targeted to pediatric leukemia harboring MLL-AF4, both as stand-alone agents and as synergistic potentiators of existing chemotherapeutic agents. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1375. doi:10.1158/1538-7445.AM2011-1375
Patients who reattend after head injury: a high risk group
Authors: M. Voss, J. D Knottenbelt, M. M Peden
Journal: BMJ (1995)

<h3>Abstract</h3> Objective: To assess risk factors for important neurosurgical effects in patients who reattend after head injury. Design: Retrospective study. Subjects: 606 patients who reattended a trauma unit after minor head injury. Main outcome measures: Intracranial abnormality detected on computed tomography or the need for neurosurgical intervention. Results: Five patients died: two from unrelated causes and three from raised intracranial pressure. On multiple regression analysis the only significant predictor for both abnormality on computed tomography (14.4% of reattenders) and the need for operation (5% of reattenders) was vault fracture seen on the skull radiograph (P&lt;10<sup>-6</sup>); predictors for abnormal computed tomogram were a Glasgow coma scale score &lt;15 at either first or second attendance (P&lt;0.0001) and convulsion at second attendance (P&lt;0.05); predictive for operation only was penetrating injury of the skull (P&lt;10<sup>-6</sup>). On contingency table analysis these associations were confirmed. In addition significant associations with both abnormality on computed tomography and operation were focal neurological abnormality, weakness, or speech disturbance. Amnesia or loss of consciousness at the time of initial injury, personality change, and seizures were significantly associated only with abnormality on computed tomography. Headache, dizziness, nausea, and vomiting were common in reattenders but were found to have no independent significance. Conclusions: All patients who reattend after head injury should undergo computed tomography as at least 14% of scans can be expected to yield positive results. Where this facility is not available patients with predictors for operation should be urgently referred for neurosurgical opinion. Other patients can be readmitted and need referral only if symptoms persist despite symptomatic treatment or there is neurological deterioration while under observation. These patients are a high risk group and should be treated seriously.
Abdominal Pain in Liver Disease
Authors: V. K. G. Pillay
Journal: BMJ (1966)

BRDITALsH 611 treated disks.A collar or traction do not achieve this.The range of extension can be increased by means of a relaxed extension lying on a block under the upper dorsal region.The active extension must be carried out lying supine, and arching up to lie on back of head and buttocks.Carried out in this way ,the spine is not weight-bearing.It must be done as a stretch, not as physical jerks.This treatment has been carried out for a good many years in the hospitals I visit, 'with gratifying results.-Iam, etc.,
Irish doctors protest over pay and conditions
Authors: D. Payne
Journal: BMJ (1999)

Hundreds of junior doctors staged demonstrations outside hospitals across the Republicof Ireland last week to protest against the state of the country's health service. The unofficial coordinated protests in Dublin, Cork, Limerick, and Galwaythe second wave in twomonthscame in advance of a planned march by medical staff on the Irish legislature on 11 September. The doctors leading …
Arterial Calcification Associated with Hypereosinophilic Syndrome
Authors: STUART N. NOVACK
Journal: Annals of Internal Medicine (1971)

Brief Communications1 January 1971Arterial Calcification Associated with Hypereosinophilic SyndromeSTUART N. NOVACK, M.D., THOMAS L. KUN, M.D., LEONARD S. GOLDBERG, M.D.STUART N. NOVACK, M.D.Search for more papers by this author, THOMAS L. KUN, M.D.Search for more papers by this author, LEONARD S. GOLDBERG, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-74-1-99 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail AbstractTwo patients with hypereosinophilic syndrome developed diffuse arterial calcification. This has not been observed previously in the hypereosinophilic syndrome.References1. ROBBINSHANELIN LJ: Soft tissue roentgenography, in Gulden's Diagnostic Roentgenography, vol. 4, edited by ROBBINS LL. Baltimore, The Williams & Wilkins Co., 1967, pp. 16.49-16.51 Google Scholar2. ANDERSON W (editor): Pathology, 4th ed. St. Louis, The C. V. Mosby Co., 1961 Google Scholar3. ROBBINS S (editor): Textbook of Pathology, 2nd ed. Philadelphia, W. B. Saunders Co., 1962 Google Scholar4. FRIEDMANNOVACKTHOMSON SSG: Arterial calcification and gangrene in uremia. New Eng J Med 280:1392-1394, 1969 CrossrefMedlineGoogle Scholar5. HARDYANDERSON WR: The hypereosinophilic syndromes. Ann Intern Med 68:1220-1229, 1968 LinkGoogle Scholar6. ZUELZERAPT WL: Disseminated visceral lesions associated with extreme eosinophilia. Amer J Dis Child 78:153-181, 1949 CrossrefMedlineGoogle Scholar7. REEDERGOODRICH WB: Pulmonary infiltration with eosinophilia (PIE syndrome). Ann Intern Med 36:1217-1240, 1952 LinkGoogle Scholar8. ENGFELDTZETTERSTRÖM BR: Disseminated eosinophilia "collagen disease." Acta Med Scand 153:337-353, 1956 CrossrefMedlineGoogle Scholar9. ODEBERG B: Eosinophilic leukemia and disseminated eosinophilic collagen disease—a disease entity? Acta Med Scand 177:129-144, 1965 CrossrefMedlineGoogle Scholar10. PIERCEHOSSEINIANCONSTANTINE LAA: Disseminated eosinophilic collagen disease. Blood 29:540-549, 1967 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, California▸From the Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, Calif. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byExtensive Eosinophilic Infiltrates in the Epidermal Cyst WallA rat model of hypereosinophilic syndromeHypereosinophilic syndrome presenting as peripheral neuropathy.Hypereosinophilic Syndrome with Pulmonary Vascular InvolvementThe Hypereosinophilic Syndrome: Clinical Features, Laboratory Findings and TreatmentEosinophilic polymyositis 1 January 1971Volume 74, Issue 1Page: 99-101KeywordsArterial calcificationMedical servicesRheumatology Issue Published: 1 January 1971 PDF downloadLoading ...
Radiation Recall Dermatitis May Represent the Koebner Phenomenon
Authors: Ross Camidge, Allan Price, Elisabeth Ortmann, Gerda Hohenberg
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.99.148 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12351618 Radiation Recall Dermatitis May Represent the Koebner Phenomenon Ross CamidgexRoss CamidgeSearch for articles by this author , Allan PricexAllan PriceSearch for articles by this author Elisabeth OrtmannxElisabeth OrtmannSearch for articles by this author , Gerda HohenbergxGerda HohenbergSearch for articles by this author Show More Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United KingdomUniversity of Vienna Medical School, Vienna, Austria https://doi.org/10.1200/JCO.2002.99.148 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01102002In Reply:As mentioned in the letter of Camidge and Price, we did not quote verbatim from their review,1 which the punctuation might have unintentionally indicated. They make, however, an important point by forwarding the theory that the radiation recall (RR) phenomenon might be a form of an idiosyncratic drug hypersensitivity reaction. Although the lack of experimental data on the RR phenomenon excludes any final judgment on their hypothesis, there are arguments against it. Despite the anecdotical reports of RR dermatitis after the administration of substances other than cytotoxic agents, the overwhelming majority of the published incidents have been reported after the administration of cytotoxic substances. The hypothesis of Camidge and Price would be supported by a low frequency of occurrence of the RR dermatitis. Although an incidence frequency has not been published yet, our own preliminary prospective observations indicate an incidence frequency of several percent, a number more compatible with a cytotoxic explanation. Our report of an RR dermatitis after the administration of a prodrug,2 which can be activated in irradiated tissue, argues for a toxic effect, especially as our observation does not seem to be the only one of its kind, as we have seen a second RR dermatitis in another patient after the administration of capecitabine while our report was in press. No matter which theory is correct, we think the RR phenomenon deserves further experimental investigation, as the occurrence of such effects in tumor tissue, which cannot be ruled out based on current knowledge, might turn a side effect into a therapeutic option.1. Camidge R, Price A: Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 59:: 237,2001-245, Crossref, Medline, Google Scholar2. Ortmann E, Hohenberg H: Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 20:: 3029,2002-3030, Link, Google Scholar
Evolution of the Eukaryotic Translation Termination System: Origins of Release Factors
Authors: Yuji Inagaki, W. Ford Doolittle
Journal: Molecular Biology and Evolution (2000)

Accurate translation termination is essential for cell viability. In eukaryotes, this process is strictly maintained by two proteins, eukaryotic release factor 1 (eRF1), which recognizes all stop codons and hydrolyzes peptidyl-tRNA, and eukaryotic release factor 3 (eRF3), which is an elongation factor 1alpha (EF-1alpha) homolog stimulating eRF1 activity. To retrace the evolution of this core system, we cloned and sequenced the eRF3 genes from Trichomonas vaginalis (Parabasalia) and Giardia lamblia (Diplomonada), which are generally thought to be "early-diverging eukaryotes," as well as those from two ciliates (Oxytricha trifallax and Euplotes aediculatus). We also determined the sequence of the eRF1 gene for G. lamblia. Surprisingly, the G. lamblia eRF3 appears to have only one domain, corresponding to EF-1alpha, while other eRF3s (including the T. vaginalis protein) have an additional N-terminal domain, of 66-411 amino acids. Considering this novel eRF3 structure and our extensive phylogenetic analyses, we suggest that (1) the current translation termination system in eukaryotes evolved from the archaea-like version, (2) eRF3 was introduced into the system prior to the divergence of extant eukaryotes, including G. lamblia, and (3) G. lamblia might be the first eukaryotic branch among the organisms considered.